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ABSTRACT
The Cancer Genome Atlas (TCGA) data indicate that high MDM2 expression
correlates with all subtypes of breast cancer. Overexpression of MDM2 drives breast
oncogenesis in the presence of wild-type or mutant p53 (mtp53). Importantly,
estrogen-receptor positive (ER+) breast cancers overexpress MDM2 and estrogen
mediates this expression. We previously demonstrated that this estrogen-MDM2
axis activates the proliferation of breast cancer cell lines T47D (mtp53 L194F) and
MCF7 (wild-type p53) in a manner independent of increased degradation of wildtype p53 (ie, p53-independently). Herein we present data supporting the role of the
estrogen-MDM2 axis in regulating cell proliferation and mammary tissue architecture
of MCF7 and T47D cells in a p53-independent manner. Inducible shRNA mediated
MDM2 knockdown inhibited colony formation in soft agar, decreased mass size and
induced lumen formation in matrigel and also significantly reduced mitosis as seen
by decreased phospho-histone H3 positive cells. The knockdown of MDM2 in both cell
lines decreased Rb phosphorylation and the level of E2F1 protein. This signaling was
through the estrogen receptor because fulvestrant (a selective estrogen receptor
degrader) decreased MDM2 protein levels and decreased phosphorylation of Rb.
Taken together these data indicate that in some ER+ breast cancers the estrogenMDM2-Rb-E2F1 axis is a central hub for estrogen-mediated p53-independent signal
transduction. This is the first indication that estrogen signaling utilizes the estrogenMDM2 axis to provoke phosphorylation of Rb and increase E2F1 while promoting
abnormal mammary architecture.

that can be targeted for cancer therapy [2–4]. MDM2
overexpression is found in many different types of cancers
[5, 6]. Some cancer patients with MDM2 overexpression
have a worse prognosis than patients with cancers that
do not have such overexpression [5]. Therefore it is not
surprising that MDM2 expression is a negative prognostic
marker for breast cancer [7]. ER+ cells exposed to estrogen

INTRODUCTION
A majority of breast cancers are estrogen–receptor
alpha positive (ER+) and many of these are resistant to
therapies targeting their hormone receptor status [1].
Many ER+ breast cancers have MDM2 overexpression
suggesting that MDM2 is an ER+ axis driver oncogene
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show an increase in their transcription of mdm2 and
increased MDM2 protein [8–11]. The mdm2 gene contains
a single nucleotide polymorphism, SNP 309, where T is
changed to G thereby further increasing estrogen activated
MDM2 expression by increased recruitment of the Sp1
transcription factor to the promoter region of the gene
[9, 12]. This mdm2 SNP309 G allele accelerates tumor
formation in a gender specific and hormone dependent
manner [9]. While estrogen signaling up-regulates MDM2,
it has not been determined if MDM2 is required for the
estrogen-mediated phenotypic changes that are associated
with tumorigenesis. Herein we investigate the estrogenMDM2 axis as a pathway that functions in some ER+ cells
to promote p53-independent tumorigenic outcomes.
There are significant pieces of evidence showing that
MDM2 has strong cancer promoting properties that are
independent of degrading p53 [11, 13–16]. Our previous
work uncovered that estrogen signaling activates MDM2mediated breast cancer proliferation in a p53-independent
manner [11]. Most notably recent work has documented
that estrogen receptor alpha mediates the p53-independent
overexpression of both MDM2 and MDM4 in human
breast cancers [13]. MDM2 expression in p53-null mice
alters the tumor spectrum and rapidly promotes tumor
formation [17]. Moreover forced MDM2 overexpression
in both wild-type and p53-null mammary glands promotes
cell cycle progression into S phase [18]. Particularly,
proliferative targets of MDM2 include the stimulation of
E2F1 transcriptional activity [19], increased E2F1 protein
stability [20], disruption of the Rb-E2F1 complex and
inhibition of tumor suppressive functions of Rb [21–23].
Estrogen treatment induces cell cycle progression through
promoting the G1 to S phase transition [24] and promotes
Rb phosphorylation [25]. This is also seen in prostate
cancer cells where MDM2 depletion reduces E2F1 and
phosphorylated Rb [26]. However, the connection between
estrogen signaling, MDM2, and the Rb-E2F1 pathway
has never been shown. We hypothesized that estrogen
signaling mediated the disruption of mammary tissue
architecture, and increased proliferative outcomes, through
an MDM2-Rb-E2F1 axis.
One of the characteristics of malignancy is the
disruption of normal mammary tissue architecture in
the specific context of the extracellular matrix [27]. The
central aspect of the mammary architecture is the acinus,
which forms terminal ductal lobular units. Each acinus
has a hollow lumen lined by a single layer of epithelial
cells. This in vivo glandular architecture is lost in 2D
culture due to loss of in vivo cell-to-cell communication
and interactions with extracellular matrix proteins. This
structure can be recapitulated when normal mammary
epithelial cells are grown in 3D laminin-rich matrigel.
Malignant cells grown in matrigel display a disrupted
architecture and form disorganized colonies with a
loss of tissue polarity and filled lumen [27]. Herein we
investigated if in 3D matrigel conditions the estrogenwww.impactjournals.com/oncotarget

MDM2 signaling axis in the MCF7 and T47D colonies
contributed to the filled lumen phenotype. We observed
that MDM2 was required for blocking hollow lumen
formation. When MDM2 was knocked down in cells grown
in matrigel, the colonies exhibited hollow lumen formation
and reduced the number of cells that were phospho-histone
H3 positive. Moreover, MDM2 knockdown in T47D and
MCF7 cells grown with estrogen in 2D conditions showed
decreased phosphorylation of Rb. The estrogen-MDM2Rb-E2F1 axis was blocked in the presence of the estrogen
receptor antagonist fulvestrant. We show for the first
time that at least in some cases the estrogen-MDM2 axis
participates in a pathway that disrupts mammary tissue
architecture, does not target p53 for degradation, and
promotes activation of the E2F1 pathway.

RESULTS
MDM2 is required for estrogen to increase 3D
colony size of estrogen receptor-positive breast
cancer cells
To determine if estrogen signaling for tumorigenic
properties requires the p53-independent MDM2 pathway
we evaluated the effect of MDM2 knockdown on estrogen
driven MCF7 and T47D proliferation in soft agar. These
ER+ breast cancer cell lines carry the mdm2 SNP309 T
to G change [9, 10, 12] and estrogen treatment induces
their anchorage-independent cell growth in soft agar
[28]. T47D cells express mtp53 L194F that does not
activate transcription of p53 targets and also does not
have oncogenic gain-of-function activity [29]. Estrogen
treatment increases the p53-independent MDM2 signaling
in T47D cell lines and also in MCF7 cells with wild-type
p53 [10, 11]. To investigate how the estrogen-mediated
increase in MDM2 protein affected anchorage independent
growth of MCF7 and T47D cells we depleted MDM2
using a mir30-based shRNA targeting strategy (described
in [11]). We evaluated MDM2 knockdown by western
blots for cells grown in 2D culture as shown in Figures
4–6. Figures 4–6 are reflective of all MDM2 knockdown
results. We observed a significant decrease in the size
and number of colonies formed in soft agar with MDM2
knockdown (Figure 1A and 1B). Representative images
of the colonies formed by T47D with and without shRNA
induction are shown in Figure 1C. In order to test the
influence of MDM2 on 3D culture colony size through an
additional method we examined the growth of MCF7 and
T47D cells in matrigel.
Matrigel conditions allow cells to recapitulate in
vivo mammary glandular architecture [30]. We previously
documented that MDM2 knockdown in MCF7 and T47D
cells leads to decreased proliferation and for MCF7 cells a
reduction in large size masses in matrigel [11]. We studied
the p53-independent role of MDM2 on T47D colonies
formed in 3D matrigel culture conditions to determine the
47917
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biological significance of estrogen signaling through the
MDM2 pathway. Reduced MDM2 caused a decrease in
matrigel colony size (Figure 1D), and this agreed with the
results presented for reduction of large soft agar colony
formation shown in Figure 1A and 1B. We stratified the
T47D masses into 5 different categories (Figure 1D, very
small (yellow), small (red), intermediate (green), large

(purple) and very large (blue)). MDM2 knockdown caused
a robust decrease in large and very large masses and an
increase in very small and small masses. The T47D.
vector control cell line did not produce small masses.
The clonal T47D.shmdm2 cell line had some very small
and small masses even without shRNA induction. This
leaky phenotype of the T47D.shmdm2 was reproducible,

Figure 1: MDM2 depletion in estrogen-treated breast cancer cells inhibits colony formation in 3D culture conditions.

(A) Number of large colonies (50μm or larger) determined by counting the colonies of MCF7 cells when grown in soft agar in the presence
of estrogen and in the presence or absence of shRNA induction (viewed by inverted fluorescence microscope). Average of three independent
experiments are shown. The number of colonies for 3 independent experiments were as follows: control vector –shRNA induction (160, 158,
175), control vector + shRNA induction (153, 151, 197), mdm2shRNA –shRNA induction (140, 137, 200) and mdm2shRNA + shRNA induction
(17, 11, 8). The p-value determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.002. (B) Number
of large colonies (100μm or larger) determined by counting the colonies of T47D cells when grown in soft agar in the presence of estrogen
and in the presence or absence of shRNA (viewed by inverted fluorescence microscope). Average of three independent experiments are shown.
The number of colonies for 3 independent experiments were as follows: control vector –shRNA induction (220, 191, 70), control vector +
shRNA induction (202, 195, 33), mdm2shRNA –shRNA induction (166, 175, 69) and mdm2shRNA + shRNA induction (27,20, 9). The p-value
determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.02. (C) Representative images of colonies
that T47D cells formed in soft agar in the presence or absence of MDM2 knockdown. (D) T47D cells grown in matrigel for 3 weeks in presence
of estrogen and in presence or absence of 4μg/ml doxycycline, were fixed and stained with propidium iodide. Colony masses were categorized in
5 different groups and the number of masses in each group were counted and presented as percentages in the total population. This is an average
of two independent experiments. The total number of masses scored for 2 independent experiments were control vector –shRNA induction (20,
15), control vector + shRNA induction (25, 27), mdm2shRNA –shRNA induction (93, 95) and mdm2shRNA + shRNA induction (86, 83). The
p-value was determined by 2-tailed Student t-test. The p-value for large and small colonies for comparisons with and without MDM2 knockdown
were p-value=0.03 and p-value=0.05 respectively. Two independent scorers counted the numbers of colonies for each independent experiment.
www.impactjournals.com/oncotarget
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and Figure 2B, bottom row for representative image). This
result was recapitulated in the ER+ MCF7 breast cancer
cells (Supplementary Figure 1A and 1B). This shows that
in some ER+ breast cancer cells the knockdown of MDM2
can revert the tumorigenic 3D filled lumen phenotype to
a hollow lumen phenotype. The fact that this occurs in
T47D cells with mtp53 supports our earlier finding that
the estrogen-MDM2 axis works, at least in part, through a
wild-type p53-independent pathway [11].

and documented by two independent scorers for two
independent experiments. We saw MDM2 knockdown
decreased colony size of MCF7 and T47D cells in two
mechanistically different experiments, repeated multiple
times, and with multiple scored colonies.

MDM2 knockdown in T47D cells grown in
matrigel promotes lumen formation
When T47D cells are grown in matrigel, they have a
cancer mass morphology with disrupted architecture and
filled lumen [30]. From the average of two independent
experiments we observed that MDM2 depletion reverted
this phenotype to become more normal (Figure 2). With
mdm2 knockdown, and not in vector induced control
samples, we observed a significant average increase in the
number of masses having hollow ductal lumen architecture
that showed a degree of luminal clearance (Figure 2A).
We observed different luminal clearance phenotypes.
A small proportion had perfect hollow lumen architecture
(representative image shown in Figure 2B, top row),
and many had variations with multiple hollow regions
(representative image shown in Figure 2B, middle row).
When MDM2 was not depleted there were significantly
less masses with hollow lumen (Figure 2A see vector
control results and MCF7.shmdm2 no induction results

MDM2 knockdown inhibits mitosis in 3D cell
culture condition
Mitosis-specific phosphorylation of histone H3 can
be used as an indicator of cells undergoing mitosis [31].
We asked if the luminal clearance phenotype associated
with decreased mitotic cells in matrigel masses. To do this
we carried out two biological replicates for two different
knockdown strategies and probed the masses with mitosisspecific anti-phospho-histone H3 followed by analysis
with confocal microscopy. MDM2 knockdown resulted
in a dramatic decrease in the average number of mitotic
cells observed in matrigel masses derived from T47D
cells with inducible MDM2 knockdown (Figure 3A)
and masses derived from T47D cells with constitutive
MDM2 knockdown (Figure 3B). A representative image

Figure 2: MDM2 depletion in ER+ breast cancer cells with mutant p53 leads to formation of lumen and reverts mammary
architecture towards a normal state. (A) T47D cells grown in matrigel for 3 weeks in presence of estrogen and in the presence or

absence of 4 μg/ml dox, were fixed, stained with F-Actin and mounted with DAPI containing mounting media. Confocal z-stack images were
acquired. Masses with lumen were counted and presented as percent of total number of masses grown in 3D matrigel. An average of two
independent experiments are shown. The number of masses counted for 2 independent experiments were control vector -shRNA induction
(21, 41), control vector +shRNA induction (21, 47), mdm2shRNA -shRNA induction (31, 46) and mdm2shRNA +shRNA induction (31,
62). The p-value determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.01. Two independent
scorers counted the numbers of masses for each independent experiment. (B) A representative image from confocal immunofluorescence
microscopy showing a single slice from z-stack of DAPI, GFP and F-Actin of estrogen treated inducible clonal T47D.shmdm2 cells grown
in 3D-matrigel in the presence or absence of 4μg/ml doxycycline (dox) for 3 weeks. The top and middle rows show hollow lumen and ductal
lumen respectively in the presence of shRNA expression to mdm2; the GFP (green) indicates shRNA induction to mdm2. The third row shows
mass structure (disruption of normal mammary glandular architecture) in the absence of shRNA expression to mdm2.
www.impactjournals.com/oncotarget
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by carrying out fluorescence activated cell sorting (FACS)
on cells grown in standard 2D culture with estrogen with
and without MDM2 depletion (Figure 3D). As predicted,
estrogen treatment increased the number of S phase
cells detected by FACS analysis and MDM2 knockdown
significantly reduced the S phase percentage (Figure 3D).
Together our data suggest MDM2 up-regulation is critical
for the estrogen-driven S-phase entrance as well as the

of inducible clonal T47D.shmdm2 cells is shown in
Figure 3C. In MCF7 cells with MDM2 knockdown we
also observed a similar decrease in cells staining with
anti-phospho-histone H3 (Supplementary Figure 1C and
1D). This supports several studies that have shown MDM2
overexpression drives cell cycle progression into S phase
of the cell cycle [18, 32]. We tested the hypothesis that the
estrogen-MDM2 axis drives the T47D cells into S phase

Figure 3: MDM2 knockdown impedes mitosis and significantly decreases the number of estrogen-driven S phase cells.

(A) & (B) T47D cells ((A) inducible shmdm2 clonal and vector pool; (B) constitutive shmdm2 and vector pool) grown in the presence
of estrogen in 3D matrigel for 3.5 weeks. The cells were fixed, permeabilized, blocked, stained with phospho-histoneH3 antibody and
mounted with DAPI containing mounting media. Images were taken with confocal microscope. Quantitative analysis of phospho-histone
H3 positive cells were performed by capturing optical Z-stack sections of masses and dividing the number of positive phospho-histone
H3 cells by the total number of masses. (A) The number of masses counted in each group for 2 independent experiments were control
vector -shRNA induction (29, 30), control vector +shRNA induction (30, 30), mdm2shRNA -shRNA induction (29, 30) and mdm2shRNA
+shRNA induction (30, 30). (B) The number of masses counted in each group for 2 independent experiments were control vector (49, 60)
and shmdm2 (48, 60). Average of two independent experiments are shown for each knockdown method. The p-value determined by 2-tailed
Student t-test comparing with and without MDM2 knockdown was p-value=0.001 (A) and p-value=0.009 (B). Two independent scorers
counted the numbers of masses for each independent experiment. (C) Representative confocal Z-stack image (single slice) showing DAPI,
phospho-histone H3 and GFP in estrogen-treated inducible clonal T47D.shmdm2 cells in the presence and absence of 4μg/ml doxycycline.
(D) Cell cycle analysis by FACS (Fluorescence Activated Cell Sorting). T47D cells were harvested, fixed and stained with propidium iodide
and subjected to cell cycle analysis by FACS. Data are presented as percent of cells in S phase in a total population of 10,000 cells and
analyzed by FACS in each group. Average of 4 independent experiments are shown. The p-value was determined by 2-tailed Student t-test
and * represents a p-value ≤ 0.05
www.impactjournals.com/oncotarget
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disruption of mammary architecture. Interestingly, from
four independent biological replicates with MDM2
knockdown the S phase was the only stage that showed a
statistically significant reduction.

significant reduction in E2F1 and a strong reduction in
phosphorylated Rb (Figure 5B).

Fulvestrant decreases MDM2 levels and blocks
phosphorylation of Rb

The estrogen-mediated proliferative advantage is
through an MDM2-Rb-E2F1 pathway

Fulvestrant is a clinically used ER antagonist
that promotes MDM2 protein turnover [33]. MDM2
has been shown to promote tamoxifen resistance and
therefore combination-fulvestrant treatments have been
proposed for patients with advanced breast cancer as a
way to target the MDM2 axis [13, 33]. We investigated
if fulvestrant could block the estrogen-MDM2-mediated
phosphorylation of Rb. We observed that fulvestrant
treatment of T47D.shmdm2 cells downregulated both
MDM2 and phosphorylated Rb levels (Figure 6A,
compare lanes 1 and 3). This down regulation was
slightly improved by shmdm2 induction (Figure 6A,
phospho Rb panel, lane 4). This decrease was observed
in three independent biological replicates with fulvestrant
alone showing a statistically significant decrease and
the combination of MDM2 knockdown plus fulvestrant
showing a trend for further reduction (Figure 6A, dot plot
of the three experiments shown below western blot). We
were interested in examining whether the combination
of fulvestrant and MDM2 knockdown also caused a
further reduction of cell viability compared to fulvestrant
treatment alone. We saw that in the presence of estrogen
the mitochondrial activity was statistically significantly
reduced by either MDM2 knockdown or fulvestrant
treatment almost to the same extent (Figure 6B).
When cells were subjected to MDM2 knockdown and
fulvestrant treatment together there was more decrease
in mitochondrial activity than with either alone, but this
was not statistically significant (Figure 6B). Therefore
fulvestrant effectively blocks the estrogen-MDM2mediated axis. We wondered if estrogen signaling to
MDM2 increased proliferation by blocking cell death.
We carried out live cell imaging to determine if either
MDM2 knockdown, or fulvestrant treatment, increased
cell death (Figure 6C, blue staining detects nuclei and red
staining showing dead cells). Neither MDM2 knockdown
nor fulvestrant treatment resulted in an increase in dead
cells further supporting that the pathway targeted by the
estrogen-MDM2 axis was involved in cell cycle regulation
(Figure 6C T47D.shmdm2 and T47D vector control).

E2F1 is known to promote cell cycle progression
so we tested if Rb phosphorylation and E2F1 protein
levels were changed by estrogen treatment and if MDM2
knockdown caused reversion. Estrogen treatment of T47D
cells reproducibly increased MDM2 protein and this was
reduced by shmdm2 induction to knockdown MDM2
(Figure 4A, lanes 1-8 top panel). Importantly estrogen
treatment increased phosphorylated Ser807/Ser811 Rb
protein levels (which correlates with activation of the
E2F pathway) and this phosphorylation was decreased
by MDM2 knockdown (Figure 4A, lanes 1-8 phospho
Rb panel). We detected a reduction of the lower 110 kD
phospho Rb band as well as multiple higher migrating
forms (Figure 4A, phospho Rb panel, compare lanes 7 and
8). The MDM2 knockdown also resulted in a decrease in
E2F1 protein (Figure 4A, E2F1 panel, compare lanes 5 and
6, and lanes 7 to 8). Estrogen treatment caused an increase
in the level of mtp53 and this mtp53 level was unchanged
by the knockdown of MDM2. We used imageJ analysis
to quantify the levels of MDM2, phosphorylated Ser807/
Ser811 Rb, and E2F1 from three independent biological
replicates for T47D.shmdm2 western blots (Figure 4B).
MDM2 knockdown caused a statistically significant
reduction of MDM2 and E2F1 and a strong reduction in
phosphorylated Rb that was not statistically significant.
Using a different knockdown method we further validated
the estrogen-MDM2-Rb-E2F1 axis from three biological
replicates of the T47D cells with constitutive MDM2
knockdown (Figure 4C and 4D). For this alternative
knockdown method we observed that constitutive MDM2
knockdown resulted in a statistically significant decrease
in the estrogen-driven phosphorylation of Rb. In these
conditions we detected only the predominant lower Rb band
at 110 kD (Figure 4C). This detection of only the lower Rb
form was due to a lower exposure of the western blot.
We investigated the estrogen-MDM2 axis signaling
to Rb in MCF7 cells. We previously published that
exposing MCF7.shmdm2 cells to estrogen increases the
amount of MDM2 protein level and depletion of the
MDM2 does not increase the p53 protein level [11]. In
this experiment, in support of the T47D data, estrogen
treatment of the control and MCF7.shmdm2 cells increased
MDM2, phosphorylated Rb, total Rb and E2F1 (Figure 5A
and 5B) and induction of mdm2 shRNA reduced MDM2
protein, phosphorylated Rb and E2F1 protein levels
(Figure 5A compare lanes 3 and 4 to lanes 7 and 8 and
see 5B). ImageJ analysis of four independent biological
replicates with MDM2 knockdown indicated a statistically
www.impactjournals.com/oncotarget

MDM2 drives Rb phosphorylation
Our data suggested that the up-regulation of MDM2
might have a direct role in increasing the phosphorylation of
Rb because estrogen stimulation of MCF7 and T47D cells
required MDM2 for the increased phosphorylation of Rb.
We wondered if MDM2 protein directly promoted signal
transduction for increased phosphorylation of Rb. To test
this we performed an in vitro kinase assay with the addition
47921
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Figure 4: In ER+ T47D breast cancer cells MDM2 influences estrogen mediated cell proliferation through the Rb-E2F1
pathway. (A) Inducible clonal T47D cells with mdm2 shRNA or control vector were treated with or without 4μg/ml doxycycline (dox) for

3 days, followed by 10nM estrogen for 5 days in the presence or absence of dox. A representative image of western blot analysis of MDM2,
phospho Rb, E2F1, p53 and Actin protein levels from 50μg whole cell protein extract is shown. (B) ImageJ analysis was performed for
MDM2, phospho Rb and E2F1 protein levels normalized to Actin. The graph represents an average of three independent experiments with
standard deviation in inducible clonal T47D cells with mdm2 shRNA or control vector. (C) A constitutive pool of T47D cells with mdm2
shRNA or control vector were grown with or without 10nM estrogen for 5 days. A representative image of western blot analysis of MDM2,
phospho Rb, E2F1, total Rb and Actin protein levels from 50μg whole cell protein extract is shown. (D) ImageJ analysis was performed
for MDM2, phospho Rb and E2F1 protein levels normalized to Actin. Graph represents average of three independent experiments with
standard deviation in constitutive pool of T47D cells with mdm2 shRNA or control vector. * represents a p-value ≤ 0.05, ** represents a
p-value ≤ 0.01, *** represents a p-value ≤ 0.001. The p-value was determined by 2-tailed Student t-test.
www.impactjournals.com/oncotarget
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of bacterially purified MDM2 to MCF7 and T47D cancer
cell extract from cells grown with or without overnight
estrogen treatment. We observed that MCF7 cell extract
(Figure 6D on the left) supported increased phosphorylation
of Rb in three independent biological replicates with a
lower but not higher amount of MDM2 (Figure 6D, left
side and dot plot for low MDM2 addition shown below).
The increased MDM2 did not decrease total Rb so less
phosphorylation of Rb might be due to other alterations in
post-translational modifications but not degradation. We
observed a similar (but less robust) result in T47D extract
(Figure 6D, right side). Taken together, our data suggest that
estrogen provokes signals to increase MDM2 expression

and this estrogen stimulated MDM2 promotes signal
transduction for increasing phosphorylation of Rb.

DISCUSSION
The p53-independent oncogenic functions of
MDM2 are less well understood than the MDM2
canonical wild-type p53 feedback pathway. Many breast
cancers contain no functional wild-type p53 and have
high expression of MDM2. MDM2 overexpression is
directly related to ER alpha overexpression [2, 4, 13, 34].
A recent analysis of The Cancer Genome Atlas (TCGA)
invasive breast cancer data found significantly higher

Figure 5: In ER+ MCF7 breast cancer cells MDM2 influences estrogen mediated cell proliferation through the Rb-E2F1
pathway. (A) Inducible clonal MCF7 cells with mdm2 shRNA or control vector were treated with and without 2μg/ml doxycycline(dox)

for 3 days to induce shRNA expression, followed by 10nM estrogen for 5 days in the presence and absence of dox. A representative image
of western blot analysis of phospho Rb, Total Rb, E2F1, MDM2 and Actin protein levels from 50μg whole cell protein extract is shown.
(B) ImageJ analysis was performed for phospho Rb, E2F1 and MDM2 protein levels normalized to Actin. Graph represents average of four
independent experiments with standard deviation in inducible clonal of MCF7 cells with mdm2 shRNA or control vector. * represents a
p-value ≤ 0.05, ** represents a p-value ≤ 0.01. The p-value was determined by 2-tailed Student t-test.
www.impactjournals.com/oncotarget
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mdm2 mRNA in ER alpha-positive tumors without a
correlation to p53 wild-type or mutant status [13]. This
analysis also showed that a high ER alpha level correlates
with increased expression of both MDM2 and MDM4
and that ER alpha-targeting therapies down-modulate
both MDM2 and MDM4 expression [13]. We, and others,

have observed that estrogen provokes p53-independent
proliferative effects [10, 11, 13, 33]. In this paper we
present data that suggests that the estrogen-MDM2 axis
signals a cascade resulting in the phosphorylation of Rb.
Massive amounts of publicly available breast cancer
data are available to evaluate the in vivo breast cancer

Figure 6: Fulvestrant treatment inhibits MDM2 expression and blocks the Rb-E2F1 pathway. (A) T47D.shmdm2 cells were

treated with 10nM estrogen (lane 1) and either had MDM2 knockdown (lane 2) or 10μM fulvestrant treatment (lane 3), or both (lane 4) for 5
days. A representative western blot analysis of MDM2, phosphoRb and Actin protein levels from 50μg whole cell protein extract is shown.
Dot plot diagram shows quantified ImageJ values of phospho Rb protein levels normalized to Actin from three independent experiments. (B)
MTT assay was performed in T47D.control vector and inducible T47D.shmdm2 clonal cell lines after treatments. Percentage mitochondrial
activity represents an average of 2 independent experiments. (A) & (B) * represents a p-value ≤ 0.05, *** represents a p-value ≤ 0.001,
**** represents a p-value ≤ 0.0001. The p-value was determined by 2-tailed Student t-test. (C) A representative live cell image by confocal
microscopy with 20X objective of T47D.vector and inducible clonal T47D.shmdm2 clonal cell lines after treatments. Red fluorescence
represents staining with propidium iodide. Blue fluorescence represents staining of nuclear DNA. (D) MDM2 drives phosphorylation of
Rb in ER+ breast cancer cells. In vitro kinase assay was performed to detect phosphorylation of Rb with or without overnight estrogen
treatment in either presence or absence of bacterially expressed and purified MDM2 (1μl or 2μl). A representative image of Western blot
analysis of MDM2, phospho Rb and total Rb protein level from nuclear extract of MCF7 (left) and T47D (right) cells are shown. Dot plot
diagram shows quantified ImageJ values of phospho Rb protein levels normalized to lamin A from three independent experiments, when
1μl of purified MDM2 was added to the nuclear extracts of MCF7 (left) and T47D (right) cells. The p-value for MCF7 cells with overnight
estrogen treatment and addition of purified MDM2 (compare lane 4 to lane 5) was statistically significant. The p-value was determined by
2-tailed Student t-test.
www.impactjournals.com/oncotarget

47924

Oncotarget

relationships between MDM2 and phosphorylated Rb [35].
We used the cBioportal http://www.cbioportal.org/ with
the TCGA breast cancer data from http://cancergenome.
nih.gov/ to evaluate the correlation between MDM2
protein expression and phosphorylated Rb in patient tumor
tissue (Supplementary Figure 2). We observed a positive
correlation between phosphorylated Rb and MDM2
protein expression (Pearson r = 0.192; p-value=0.0638)
and a negative correlation between total Rb and MDM2
protein expression (Pearson r = -0.108; p-value=0.2983).
The correlation between MDM2 and phosphorylated Rb
was strengthened by the fact that high MDM2 did not have
a strong correlation with changes in total Rb. This argues
for a true relationship between increased MDM2 in breast
cancers and the activation of the Rb-E2F1 pathway. Our
data support that an estrogen-MDM2 axis activates the
Rb-E2F1 pathway in at least a subset of breast cancers.
We examined estrogen-driven breast cancer
cell growth in 3D culture and asked if MDM2 was
necessary for the hormone-dependent growth properties.
Interestingly we found that growth of MCF7 and T47D
cells in soft agar in the presence of estrogen required
MDM2 expression. The knockdown of MDM2 prevented
cells with either wild-type p53 or mutant p53 from
achieving estrogen-mediated anchorage independent cell
growth. This not only demonstrated that estrogen was
signaling through up-regulation of MDM2 for mammary
tumorigenic related phenotypes but also that MDM2
provided this function in the absence of promoting the
degradation of p53. We studied the p53-independent
MDM2-mediated cell morphology in more depth by

examining the influence of MDM2 on estrogen-mediated
growth in a laminin rich matrigel environment. We
observed that MDM2 expression was required for the lack
of luminal clearance that associates with breast cancer cell
growth in matrigel and that knockdown of MDM2 resulted
in luminal clearance. This is the first report of estrogen
working through an MDM2 pathway, which leads to the
disruption of mammary architecture, and signaling for
the phosphorylation of Rb (see model in Figure 7). Our
preliminary data with the triple negative breast cancer
(TNBC) cell line MDA-MB-231 suggests no influence
of MDM2 on proliferation in the absence of receptor
signaling. The knockdown of MDM2 in estrogen receptor
negative (ER-) MDA-MB-231 cells did not decrease cell
proliferation (Supplementary Figure 3). Therefore in T47D
and MCF7 cells there may be some MDM2-mediated
cross-talk with estrogen driven factors.
Estrogen signaling has been shown to up-regulate
Rb phosphorylation [25] and MDM2 decreases total Rb
while increasing phosphorylated Rb [21, 26]. However
there has never been a connection made showing that
the estrogen axis requires signaling to MDM2 for Rb
phosphorylation thus indicating an estrogen-MDM2-RbE2F1 axis. We observed that MDM2 was required in T47D
and MCF7 cells in order for estrogen to stimulate the
phosphorylation of Rb. Interestingly while we observed
an increase in phosphorylated Rb, we did not observe a
decrease in total Rb. We have demonstrated for the first
time that there is an estrogen-MDM2-Rb-E2F1 axis in
some breast cancer cells.

Figure 7: Schematic representation of MDM2 signaling pathway showing a p53-independent function of MDM2 is
required for estrogen mediated breast cancer proliferation and disruption in 3D mammary architecture. Model showing
that MDM2 is a central hub in estrogen signaling and works through an Rb-E2F1 pathway to promote proliferation. Breast cancer cells
harboring SNP309 have increased binding of the transcription factor Sp1, which causes elevated MDM2 protein levels. Fulvestrant blocks
the MDM2 pathway and the Rb-E2F1 pathway.
www.impactjournals.com/oncotarget
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Fulvestrant is a novel hormone receptor antagonist
that causes rapid degradation of both the ER and the
progesterone receptor (PgR) [36] and has been shown to
be highly effective for treating late stage breast cancer
[37]. Mechanistically, fulvestrant can block the estrogen
mediated increased in MDM2 [13, 33]. We observed that in
addition to blocking the up-regulation of MDM2, fulvestrant
also downregulated Rb phosphorylation. Moreover, the
combination of fulvestrant with MDM2 knockdown caused
a slight reduction in phosphorylated Rb beyond fulvestrant
alone (although not statistically significant). We observed that
the addition of MDM2 to breast cancer cell extracts in vitro
modestly increased the phosphorylation of Rb. However,
only low and not high MDM2 increased Rb phosphorylation.
It is possible that a fine tuned regulation of ubiquitination
activates Rb phosphorylation while increased ubiquitination
blocks Rb phosphorylation. MDM2 has been shown to
ubiquitinate Rb and the level of ubiquitination is reduced
by the deubiquitinase HAUSP [38]. MDM2 knockdown
and fulvestrant treatment reduced Rb phosphorylation.
Fulvestrant blocks estrogen-mediated increases in MDM2 by
increasing MDM2 protein turnover [33]. Fulvestrant alone
causes G1 cell cycle arrest that is p53-independent and our
live cell confocal microscopy indicated that this fulvestrant
and/or MDM2 knockdown did not increase cell death. Our
data supports the use of fulvestrant as a way to target the
estrogen-MDM2 signal transduction pathway. Combination
of fulvestrant with doxorubicin, etoposide or paclitaxel is
synergistic for inhibiting breast cancer proliferation and
induces cell death by suppressing MDM2 expression [33].
The results presented here support the idea that targeting
the MDM2 pathway by fulvestrant treatment of estrogenreceptor positive breast cancers that are not resistant to
fulvestrant may be an excellent mechanism to target the
cancer at multiple estrogenic hubs. New MDM2 targeting
agents are in clinical trials. Fulvestrant resistant ER-positive
breast cancers have reduced ER and increased ERBB2 [39].
Such resistant breast cancers pose a challenge and it will be
interesting to see if fulvestrant resistant breast cancers have
up-regulation of MDM2. If fulvestrant-resistant cancers have
up-regulated MDM2 they might be excellent candidates for
treatment with MDM2 blocking therapies.

were generated as described previously [11]. A T47D cell
pool with constitutive knockdown of mdm2 was generated
for this work by infection with MLP vector (a generous gift
from Scott Lowe) containing mdm2 151656 shRNA or empty
vector by the retroviral mediated gene transfer method. In
short, empty or shmdm2 containing vector were transfected
using the calcium phosphate method to Phoenix packaging
cells to make virus that was used to infect T47D cells and
then they were selected with 5μg/ml puromycin.

Anchorage independent growth assay
Cells were grown in 2D culture for 3 days with
or without doxycycline. They were trypsinized, washed
with 1X clear HBSS three times and then counted.
Cells with equal seeding densities were mixed with
0.3% Noble Agar (Sigma A5431) in phenol-red-freeDMEM media containing 10% charcoal stripped FBS
(Gemini), antibiotics, 10nM estrogen and with or without
doxycycline. They were seeded onto 35mm dishes coated
with 0.5% Nobel agar in the same media. They were
then toped with the same media. Estrogen-treated growth
medium with or without doxycycline was replaced every
3 days. Colonies were counted after 3-3.5 weeks.

Cell culture in matrigel
Cells were grown in 2D culture for 3 days with
or without doxycycline. They were trypsinized, washed
with 1X clear HBSS three times and then counted. They
were seeded on top of 40μl solidified matrigel (Cultrex) in
phenol-red-free-DMEM media containing 10% charcoal
stripped FBS (Gemini), antibiotics, 10nM estrogen and
with or without doxycycline. Medium was changed
every 3 days. Masses were grown for 3-3.5 weeks, fixed
with 4% paraformaldehyde, permeabilized, blocked and
stained with propidium iodide or actin immunostaining
by Rhodamine-Phalloidin (Cytoskeleton BK005) or
primary antibody phospho histone H3 (Millipore)
followed by Alexa Fluor conjugated secondary antibody
(Invitrogen) and mounted with Vectashield mounting
medium containing DAPI (Fisher Scientific). Imaging was
performed using confocal microscope using laser scanning
spectral confocal microscope TCS SP2.

MATERIALS AND METHODS

Treatments

Cell culture

Inducible shmdm2 or vector control cell lines were
grown in complete media described above, with or without
doxycycline (4μg/ml for T47D, and 2μg/ml for MCF7,
and 6μg/ml for MDA-MB-231) for shRNA induction
for 3 days. The growth medium was then replaced with
phenol-red-free DMEM media containing 10% charcoal
stripped FBS (Gemini) and antibiotics and treated with
10nM estrogen (17-beta-estradiol, Sigma) and/or 10μM
fulvestrant (Sigma-Aldrich) wherever applicable. Fresh
medium was applied every 72 hours.

2D culture: Human breast cancer cells T47D (mdm2
SNP309 G/G, mutant p53 L194F), MCF7 (mdm2 SNP309
T/G, wild-type p53), and MDA-MB-231 (mdm2 SNP309
T/G, mutant p53 R280K) cells were obtained from American
Type Culture Collection (ATCC). They were grown in
DMEM (Invitrogen), supplemented with 10% fetal bovine
serum (FBS, Gemini) and 50U/ml penicillin and 50μg/ml
streptomycin (Mediatech) at 5% CO2 in a 37oC humidified
incubator. Cell lines with the inducible mdm2 knockdown
www.impactjournals.com/oncotarget
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MTT assay

1:3 (bead to supernatant) and rocked for an hour at 4oC.
After a quick spin as the beads settled, the supernatant
was transferred and labeled as “unbound”. The pellet was
washed with wash buffer (pH 6.3: 100mM Na2H2PO4,
10mM Tris-Cl, 8M Urea, 1mM PMSF) in 1:2 (bead to
buffer) 2 times and the supernatant was labeled as “wash”.
The remaining pellet was mixed in 2.5 X the elution buffer
(pH 5.9: 100mM Na2H2PO4, 10mM Tris-Cl, 8M Urea,
100mM EDTA pH8, 1mM PMSF) and supernatant was
collected after quick spun and labeled as “elute”. This was
repeated 2 more times. Small aliquots were taken at each
elution and run on a gel to confirm purification of MDM2
compared to wash and unbound. The third elute of purified
MDM2 was used in in vitro kinase assay.

Cell viability was often measured as mitochondrial
activity using tetrazolium dye-based microtitration assay.
Cells were seeded at 20 x 103 per well in 12-well plate.
After treatment, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) assay was performed as per
manufacturers instructions (Sigma). The absorbance was
quantified by measuring absorbance at 550nm (the 620nm
absorbance was subtracted from the background). Data
represent percentage mitochondrial activity in each sample
relative to the untreated sample.

Live cell imaging
Cells were seeded at 20 x 103 per well in a 12-well
glass bottom plate (MatTek, Ashland, MA, USA). After
treatment, cells were stained with 50 ul ReadyProbes
Cell Viability Imaging Kit Blue/Red (Life Technologies
Cat# R37610) for 15 min at room temperature and z-stack
images of stained cells were taken by confocal microscopy
using a Nikon A1 confocal microscope with 20x objective.
Maximum projection images are shown. Propidium
iodide: red fluorescence; Nuclear DNA: blue fluorescence.

Nuclear extracts
Pellets were collected of cells with and without
overnight estrogen treatment. The pellets were suspended
in 5X packed cell volumes with cytoplasmic extraction
buffer (CEB: 10mM Hepes pH 7.9; 1.5mM MgCl2; 10mM
KCl; 0.5mM PMSF, 0.5 mM DTT; 8.5μg/ml Aprotinin,
2μg/ml Leupeptin; and phosphatase inhibitor mixture I
(Sigma)). After washing, cells were resuspended with
a 20-gauge needle in 2X packed cell volumes of CEB
and incubated on ice for 10 min. After centrifugation
(10 min at 12,000 rpm at 4 °C) the supernatant was
removed to give the cytoplasmic fraction. The pellet was
resuspended in kinase reaction buffer (20 mmol/L Tris
pH 7.5; 7.5 mmol/L MgCl2; 1 mmol/L DTT; 0.5 mmol/L
ethyleneglycol-bis [beta-aminoethyl]-N,N,N′,N′-tetraacetic
acid [EGTA]; 25 mmol/L beta-glycerophosphate; 0.5
mmol/L sodium orthovanadate; 1 mmol/L PMS; 2 μg/ml
leupeptin, 1.5 μg/ml aprotinin and phosphatase inhibitor
mixture). Cells were resuspended with a 20-gauge needle
and the cell suspension was rocked for 30 min at 4 °C and
then centrifuged for 30 min at 13,000 rpm at 4 °C. The
supernatant was the nuclear fraction.

Fluorescence activated cell sorting (FACS)
FACS was performed on FACScan device (BD
Biosciences). After treatments, cells were harvested,
washed, resuspended in PBS containing 2% bovine serum
albumin, 0.1% sodium azide, fixed in 30% ethanol and
stored overnight at 4oC. Before sorting, propidium iodide
staining and RNAse treatment were performed for 30
minutes at 37oC.

Whole cell protein extract
Cells were pelleted from 2D culture at 1100 rpm
for 7 mins at 4oC and washed 3 times with 1X ice-cold
PBS. The cells were then suspended in RIPA buffer (0.1%
SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150mM
NaCl, 1mM EDTA, 0.5mM EGTA, 50mM Tris-Cl pH8)
with 1mM PMSF, 8.5μg/ml Aprotinin, 2μg/ml Leupeptin,
sodium fluoride (5mM), sodium orthovanadate (1mM) and
phosphatase cocktail inhibitor (Sigma) following standard
protocol.

In vitro kinase assay
The breast cancer cell nuclear extract made in kinase
buffer was incubated with 1μl or 2μl of purified MDM2
in elution buffer or elution buffer alone (control) and
ATP regeneration system (1mM ATP, 1mM magnesium
chloride, 10mM phosphocreatine, 50μg/ml creatine
kinase) for 30 minutes at 30oC. The total reaction volume
was 50μl. The reaction was terminated with 4X NuPAGE
Lithium dodecyl Sulfate buffer (Life Technologies) and
western blot assay was performed immediately.

Purification of MDM2 expressed in bacteria
After IPTG induction for 4 hours, BL21DE3
(having plasmid pRSETA HDM2; generous gift from
Lindsey Mayo lab) bacterial cell pellets were collected
and lysed with lysis buffer (pH 8: 100mM Na2H2PO4,
10mM Tris-Cl, 8M Urea, 1mM PMSF) by frequent
vortexing. It was then centrifuged for 25 minutes in 4oC
at 10,000g. The supernatant was collected, mixed with
Ni-NTA agarose beads (Qiagen, #30210) in the ratio of
www.impactjournals.com/oncotarget

Western blot assay
Protein extracts from 2D culture were prepared
with 4X NuPAGE Lithium dodecyl Sulfate buffer (Life
Technologies) and 20mM DTT. The samples were heated
at 70oC for 10 min and then 100 mM Iodoacetamide
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